
45% HPMC











FIG. 4A














FIG. 4M




FIG. 4N




FIG. 40




FIG. 4P




FIG. 4Q





FIG. 4R



# FIG. 4S FIG. 4U FIG. 4V FIG. 4T Million Million FIG. 4X FIG. 4W FIG. 4Y FIG. 4AA FIG. 4AB




FIG. 6







FIG. 7

Mean Plasma Concentration of Glipizide (n=3)



Deconvolved Cumulative Input 00 5





-c- Covera-MS --- Calan-SR Commercial Verapamil Formulation Dissolution Profiles 29 5 Time (hr) FIG. 10 6 Ŋ 120 8 100 00 40 20 Percent Dissolved (%)

D9887318 D52101

S → Low Viscosity HPMC (8 dips) --- Low Viscosity HPMC Veramapii Tablet Formulation Dissolution Profiles (no dip-coat) 20 <u>\_</u> Time (hr) S 120 100 00 40 20 (%) beviossid inecrea


roffgggaerezaaeo

2 Verapamil Tablet Formulation Dissolution 8 Time (hr) Profiles → HPMC: 4K (with Dip-Coat) --- HPMC: 4K (No Dip-Coat) FIG. 12 80 2 (%) beviossig insorae


HOTELO BANKBERO

FIG. 13


Verapamil Tablets Dissolution Profiles




## **FIG. 14A**




# **FIG. 14B**



#### FIG. 14C



## FIG. 14D



#### **FIG. 14E**

